B
BioSpace
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
0:00-20:19
September has been a rough month already for Novo Nordisk, which canned two more late-stage trials of its embattled IL-6 inhibitor, and Novartis, which took Phase 3 hits in both cardiovascular and muscular dystrophy indications; Ultragenyx’s big bet in Angelman syndrome failed to yield benefit in Phase 3 but Ionis’ Pharmaceuticals nabbed the first targeted approval for Alexander disease; and on the business side, biopharma investment is back in a big way.
Publisher
BioSpace
Published
September 9, 2026
Duration
20 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
B
BioSpace
@biospace
#novoscannedheart #novartisclinicalfails #alexanderdisease #lifesciences
